TWi Pharmaceuticals Inc (安成藥業) yesterday delisted its stock from the local bourse after chairman Chen Chih-ming (陳志明) acquired about 87 percent of its shares through a public tender offer.
About 2,800 shareholders had not sold their shares as of yesterday, the company said.
Chen’s Calchen Pharmaceuticals Inc (加陳國際藥業) would swap shares with shareholders at an exchange ratio of one-to-one, which would allow shareholders to gain preferred stocks of Calchen and then choose to hold them or sell them to Calchen at NT$72 per share in the next three months, Twi spokeswomen Angela Luan (欒君儀) said by telephone.
After the stock swap, Calchen would own 100 percent of TWi, making TWi a wholly owned subsidiary, Luan said.
The Chinese-language Wealth Magazine reported that Chen’s acquisition has not been without criticism, saying minority shareholders have complained that the firm’s downbeat outlook delivered to an investors’ conference in March dragged share prices down.
However, revenue performance for the first half of this year was strong and beat market estimates, as sales for June skyrocketed 96.29 percent year-on-year and cumulative sales for the first half rose 43.2 percent, the company’s data showed.
Luan defended the company’s earlier sales guidance, saying that TWi routinely shared information with investors about its applications for market approval of its drugs and expectation for revenue growth, and was not trying to hide information.
“Sometimes our forecast did not materialize, as regulators delayed reviews or decisions on drug products,” she said.
It usually takes about a year to see a firm’s revenue expand after its gains marketing approval for its drugs, she said.
The generic drug industry is in a trough, Luan said, citing Pfizer Inc’s announcement last week that its off-patent drug unit would merge with Mylan NV.
Big pharmaceutical companies prefer to conduct mergers and acquisitions when the industry is sluggish, she said.
In other developments, SynCore Biotechnology Co Ltd (杏國新藥) yesterday said it has enrolled 108 patients for its phase III clinical trials of its pancreatic cancer drug SB05PC in Taiwan and six other nations.
As it has met the requirement for the number of patients for the interim analysis, it plans to conduct the analysis by the end of this year, the company said.
It has to enroll a total of 218 patients in the trial, something it expects to complete by March next year, and then complete the trail in the fourth quarter, it said.
In those seven markets, the drug would be used as a second-line treatment in combination with gemcitabine for those who have exhausted the first-line chemotherapy treatments.
SB05PC combined with standard gemcitabine chemotherapy has produced an overall survival period of 13.7 months in the phase II trial, exceeding the 6.8 months of the standard gemcitabine chemotherapy, the company said.
It is confident of successful results in its phase III trial, it said.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to